Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Hematopoietic Stem Cell Transplantation

Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission

Leukemia volume 15, pages 757–763 (2001)Cite this article

Abstract

In order to improve leukemia-free survival we evaluated the feasibility and efficacy of autologous transplantation of interleukin-2 (IL-2)-mobilized peripheral blood progenitor cells for adult patients with acute myelogenous leukemia in first remission. Forty-nine consecutive patients (median age 49, range 21–70) with acute myelogenous leukemia in first remission were enrolled on a study of high-dose cytarabine/mitoxantrone consolidation chemotherapy with post-recovery IL-2 used as a method of in vivo purging for the purpose of autologous peripheral blood progenitor cell transplantation. A median of 2.08 × 106 CD34+ peripheral blood progenitor cells/kg were infused 1 day after preparative conditioning with 11.25 Gy total body irradiation and cyclophosphamide (120 mg/kg). Forty-one patients received myeloablative chemo-radiotherapy followed by the infusion of IL-2-mobilized autologous peripheral blood progenitor cells. The median times to both neutrophil and platelet recovery were 16 days (range, 2–43) and 23 days (8–318+ days), respectively. Twenty-seven patients remain alive with 24 in continued first complete remission. Median remission duration for all eligible patients is 8 months, and actuarial leukemia-free survival is 49 ± 15%. The actuarial risk of relapse is 43 ± 16%. Toxicity of autologous peripheral blood progenitor cell transplant included treatment-related death in three patients and serious organ toxicity in 12. Advanced age was a negative prognostic factor for leukemia-free survival. Results were compared to an age-matched historical control treated with autologous transplantation of chemotherapy-mobilized progenitor cells; no significant difference in favor of IL-2 mobilization could be demonstrated. Our results demonstrate that autologous transplantation of IL-2-mobilized peripheral blood progenitor cells is feasible in an unselected population of adult patients with acute myelogenous leukemia in first remission with minimal toxicity but no clear evidence of benefit in leukemia-free survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura, GA, Moor JO, McIntyre OR, Frei E, for the Cancer and Leukemia Group B . Intensive postremission chemotherapy in adults with acute myeloid leukemia New Engl J Med 1994 331: 896–903

    Article  CAS  PubMed  Google Scholar 

  2. Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL . Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission J Clin Oncol 1992 10: 41–46

    Article  CAS  PubMed  Google Scholar 

  3. Applebaum FR, Dahlberg S, Thomas ED, Buckner CD, Cheever MA, Clift RA, Crowley J, Deeg HJ, Fefer A, Greenberg PD, Kadin M, Smith W, Stewart P, Sullivan P, Storb R, Weiden P . Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison Ann Intern Med 1984 101: 581–588

    Article  Google Scholar 

  4. Berman E, Little C, Gee T, O'Reilly R, Clarkson B . Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation New Engl J Med 1992 326: 156–160

    Article  CAS  PubMed  Google Scholar 

  5. Cassileth PA, Anderson J, Lazarus HM, Colvin OM, Bennet JM, Stadtmauer EA, Kaizer H, Weiner RS, Edelstein, M, Oken MM . Autologous bone marrow transplant in acute myeloid leukemia in first remission J Clin Oncol 1993 11: 314–319

    Article  CAS  PubMed  Google Scholar 

  6. Lowenberg B, Verdonck LJ, Dekker AW, Willemze R, Zwaan FE, de Planque M, Abels J, Sonneveld P, van der Lelie J, Goudsmit R, van Putten WLJ, Sizoo W, Hagenbeek A, De Gast GC . Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study J Clin Oncol 1990 8: 287–294

    Article  CAS  PubMed  Google Scholar 

  7. Korbling M, Hunstein W, Fliedner TM, Cayeux S, Dorken B, Fehrentz D, Haas R, Ho AD, Keilholz U, Knauf W, Konig A, Mende V, Pezzuto A, Von Reumotn J, Wolf GK, Wannemacher M, Zum Winkel K, Rother K . Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia Blood 1989 74: 1898–1904

    CAS  PubMed  Google Scholar 

  8. Schiller G, Lee M, Lill M, Mittal-Henkle A, Paquette R, Sawyers C, Territo M . Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission Leukemia 1997 11: 1533–1539

    Article  CAS  PubMed  Google Scholar 

  9. Lotzova E . Role of interleukin 2 activated MHC-non restricted lymphocytes in antileukemia activity and therapy Leuk Lymphoma 1992 7: 15–28

    Article  CAS  PubMed  Google Scholar 

  10. Foa R, Guarini A, Tos AG, Cardona S, Fierro MT, Meloni G, Tosti S, Mandelli F, Gavosto F . Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin-2 evidence of in vivo lymphokine activated killer cell generation Cancer Res 1991 51: 964–968

    CAS  PubMed  Google Scholar 

  11. Margolin KA, Wright C, Forman SJ . Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells Leukemia 1997 9: 723–728

    Article  Google Scholar 

  12. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE . A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone New Engl J Med 1987 316: 889–897

    Article  CAS  PubMed  Google Scholar 

  13. Bennett JM, Catovsky DM, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C . Proposals for the classification of acute leukemias. French–American–Bristish (FAB) Co-operative Group Br J Haematol 1997 33: 451–458

    Article  Google Scholar 

  14. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, Champlin R . Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelocytic leukemia Blood 1992 80: 2977–2982

    CAS  PubMed  Google Scholar 

  15. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  16. Allison, PD . Survival Analysis Using the SAS System: A Practical Guide Cary, NC 1998

    Google Scholar 

  17. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP . High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results J Clin Oncol 1989 7: 1260–1267

    Article  CAS  PubMed  Google Scholar 

  18. Champlin R, Gajewski J, Nimer S, Vollset S, Landaw E, Winston D, Schiller G, Ho W . Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment J Clin Oncol 1990 8: 1199–1206

    Article  CAS  PubMed  Google Scholar 

  19. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F . Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy Br J Haematol 1991 77: 497–501

    Article  CAS  PubMed  Google Scholar 

  20. Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernant JP, Sauvage C, Troussard X, Nedellec G, Pico J, Huguet F, Stoppa AM, Broustet A, Sotto J, Pris J . Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group Blood 1995 86: 1619–1628

    CAS  PubMed  Google Scholar 

  21. De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lonnqvist B, Beelen D, Ferrant A, Gmur J, Liu Yin J, Troussard X, Cahn J, Van Lint M, Gratwohl A . Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group Br J Haematol 1990 74: 151–155

    Article  CAS  PubMed  Google Scholar 

  22. Runde V, De Witte T, Aul C, Gratwohl A, Niederwieser D, van Biezen A, Hermans J, Vernant J, Jolb H, Vossen J, Lonqvist B, Beelen D, Ferrant A, Arnold R, Cahn J, van Lint M, Verdonk L, Apperley J . Myelodysplastic syndromes (MDS) or leukemia following MDS (sAML) treated with allogeneic bone marrow transplantation (BMT): a survey of the working party on chronic leukemia of the EBMT Ann Hematol 1995 70: (Suppl. II) A138

    Google Scholar 

  23. Cassileth PA, Harrington DP, Appelbaum FR . Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission New Engl J Med 1998 339: 1649–1656

    Article  CAS  PubMed  Google Scholar 

  24. Fefer A, Robinson N, Benyunes MC . Interleukin-2 therapy after autologous stem cell transplant for acute myelogenous leukemia in first remission. In: Dicke K, Keating A (eds).Autologous Blood and Marrow Transplantation Proceedings of the Ninth International Symposium Carden Jennings: Arlington, Texas 1999 46–53

  25. Fefer A . Graft-versus-tumor responses: adoptive cellular therapy in bone marrow transplantation. In: Forman SJ, Blume KG, Thomas ED (eds) Bone Marrow Transplantation Blackwell: Boston 1994 p 231

    Google Scholar 

  26. Foa R . Does interleukin-2 have a role in the management of acute leukemia? J Clin Oncol 1993 11: 1817–1825

    Article  CAS  PubMed  Google Scholar 

  27. Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA . Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2 J Immunol 1986 137: 3675–3680

    CAS  PubMed  Google Scholar 

  28. Johnson CS, Thurlow SM, Furmanski P . Lymphokine-activated killer cell plus recombinant interleukin-2 therapy of erythroleukemia in mice Leukemia 1989 3: 91–96

    CAS  PubMed  Google Scholar 

  29. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H . Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells Blood 1986 68: 938–948

    CAS  PubMed  Google Scholar 

  30. Fierro MT, Liao XS, Lusso P, Bonferroni M, Matera L, Cesano A, Lista P, Arione R, Forni G, Foa R . In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity Leukemia 1988 2: 50–54

    CAS  PubMed  Google Scholar 

  31. O'Brien D, Boughton B . High and low affinity IL-2 receptors on human leukaemic blast cells Br J Haematol 1990 76: 315–317

    Article  CAS  PubMed  Google Scholar 

  32. Maraninchi D, Blaise D, Viens P, Brandely M, Olive D, Lopez M, Sainty D, Marit G, Stoppa AM, Reiffers J . High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse Blood 1991 78: 2182–2187

    CAS  PubMed  Google Scholar 

  33. Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Gavosto F, Mandelli F . Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study Br J Haematol 1991 77: 491–496

    Article  CAS  PubMed  Google Scholar 

  34. Macdonald D, Jiang YZ, Gordon AA, Mahendra P, Oskam R, Palmer PA, Franks CR, Barrett AJ . Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study Leukemia Res 1990 14: 967–973

    Article  CAS  Google Scholar 

  35. Meloni G, Foa R, Tosti S, Vignetti M, Mancini F, Guarini A, Marchis D, Gavosto F, Mandelli F . Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study Leukemia 1992 6: 780–785

    CAS  PubMed  Google Scholar 

  36. Robinson N, Sanders JE, Benyunes MC, Beach K, Lindgren C, Thompson JA, Appelbaum FR, Fefer A . Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia Blood 1996 87: 1249–1254

    CAS  PubMed  Google Scholar 

  37. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D, Lowenberg R, Verdonck LF, de Plangin M, Hermans J, Helbig W, Porcellani A, Rizzoli V, Alexandrino EP, Franklin IM, Reiffers J, Colleselli O, Goldman JM . Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging Blood 1990 75: 1606–1614

    CAS  PubMed  Google Scholar 

  38. Blaise D, Attal M, Reiffers J, Michallet M, Bellanger C, Pico JL, Stoppa AM, Payen C, Marit G, Bouabdallah R, Sotto JJ, Rossi JF, Brandely M, Hercend T, Maraninchi D . Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission Eur Cytokine Netw 2000 11: 91–98

    CAS  PubMed  Google Scholar 

  39. Weisdorf DJ, Anderson PM, Blazar BR, Uckun FM, Kersey JH, Ramsay NKC . Interleukin-2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia – a phase I study Transplantation 1993 55: 61–66

    Article  CAS  PubMed  Google Scholar 

  40. Margolin KS, Besien KV, Wright C, Niland J, Champlin R, Fung HC, Kashyap A, Molina A, Nademanee AP, O'Donnekk MR, Parker P, Smith E, Spielberger R, Somlo G, Snyder D, Stein A, Woo D, Thomas M, Sniecinski I, Forman SJ . Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma Biol Blood Marrow Transplant 1999 5: 36–45

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Chela-Rene Spaargaren for preparation and typing of the manuscript.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology/Oncology, Room 42-121 CHS, UCLA School of Medicine, Los Angeles, CA 90095, USA

    G Schiller, S Wong, T Lowe, G Snead, R Paquette, C Sawyers, M Wolin, L Kunkel, L Ting, G Li & M Territo

Authors
  1. G Schiller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Lowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Snead
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Paquette
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Sawyers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Wolin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Kunkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Ting
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Territo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schiller, G., Wong, S., Lowe, T. et al. Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission. Leukemia 15, 757–763 (2001). https://doi.org/10.1038/sj.leu.2402113

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402113

Keywords

This article is cited by

Search

Advanced search

Quick links